Biomarkers and surrogate endpoints are critical tools for drug development

We are committed to engaging a wide range of audiences and having a dialogue on opportunities to create a better health care system. We believe health literacy can not only help patients make appropriate decisions about their own health but also help enable constructive conversations on how we can support a regulatory and policy environment that helps patients access life-saving medications. In this ongoing series, we are choosing to spotlight terms fundamental to the biopharmaceutical ecosystem and illustrate their significance in promoting innovation and timely patient access to medicines. This week, we are taking a look at the critical rolebiomarkers andsurrogate endpoints play in enhancing the drug development process.
Source: The Catalyst - Category: Pharmaceuticals Authors: Tags: Research and Development FDA PDUFA Source Type: news